Premium
The expanding morphological and genetic spectrum of MYOD1 ‐mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non‐mutated cases
Author(s) -
Tsai JenWei,
ChangChien YiChe,
Lee JenChieh,
Kao YuChien,
Li WanShan,
Liang CherWei,
Liao IChuang,
Chang YiMing,
Wang JuiChu,
Tsao ChengFeng,
Yu ShihChen,
Huang HsuanYing
Publication year - 2019
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.13819
Subject(s) - histology , pathology , biology , immunohistochemistry , mutation , medicine , genetics , gene
Aims Spindle cell/sclerosing rhabdomyosarcomas (SC/SRMS) feature spindled and/or rounded rhabdomyosarcomatous cells within variably hyalinised stroma. Only 30–67% of SC/SRMSs harbour neomorphic MYOD1 p.L122R mutations, indicating heterogeneity in this RMS type. We compared MYOD1 ‐mutant and non‐mutant cases to characterise the histological and genetic spectrum of mutated SC/SRMS. Methods and results Seventeen RMSs with spindled, sclerosing or hybrid histology were sequenced to identify MYOD1 and PIK3CA mutations and reappraised to assess histological features and myogenic immunophenotypes. Twelve SC/SRMSs harboured MYOD1 mutations, including homozygous p.L122R ( n = 8), heterozygous p.L122R ( n = 3) and heterozygous p.E118K ( n = 1). MYOD1 ‐mutant tumours affected nine females and three males aged 8–64 years (median = 22.5), had a median size of 4.2 cm (range = 2–22) and involved the head and neck ( n = 7), extremities ( n = 4) and mediastinum ( n = 1). Fascicular/spindle histology was predominant in four cases, including one with heterologous lipoblasts in focally myxoid stroma. Four sclerosing cases mainly comprised rounded cells, including one with multinucleated tumour cells. Four cases were histologically hybrid. The only PIK3CA (p.H1047R) mutation was detected in a predominantly spindled MYOD1 ‐p.L122R‐mutated case, but not in its laser‐microdissected lipoblast‐containing area. All MYOD1 ‐mutant cases exhibited diffuse MYOD1 expression but patchy myogenin reactivity. At final follow‐up (median = 13.5 months), recurrences ( n = 4), metastases ( n = 2) or both ( n = 1) occurred in seven MYOD1 ‐mutant cases; one had died of disease. Five non‐mutated cases were reclassified as spindle embryonal ( n = 3), dense embryonal ( n = 1) and unclassifiable ( n = 1) RMSs. Conclusion MYOD1 ‐mutant RMSs are uncommonly mutated with PIK3CA and behave aggressively with an expanded morphological and genetic spectrum, including lipoblastic differentiation, multinucleated cells and the alternative p.E118K mutation.